

Quarterly pharmacy formulary change notice

Summary: The formulary changes listed in the table below were reviewed and approved at our 1st quarter 2020, pharmacy and therapeutics committee meeting.

Effective August 1, 2020, the changes outlined below apply to all Amerigroup Community Care members.

Effective for all patients on August 1, 2020			
Therapeutic class	Drug	Revised status	Potential alternatives
ICS/LABA	BREO ELLIPTA INHALER 100-25 BREO ELLIPTA INHALER 200-25	NON- PREFERRED WITH PA AND CURRENT UTILIZERS WILL BE GRANDFATHERED	BUDESONIDE/FORMOTEROL INHALER (GENERIC SYMBICORT) FLUTICASONE/SALMETEROL INHALER (GENERIC AIRDUO RESPICLICK) FLUTICASONE/SALMETEROL AEROSAL WIXELA INHUB AEROSAL (GENERIC ADVAIR DISKUS)

What action do I need to take?

Please review these changes and work with your Amerigroup patients to transition them to formulary alternatives. If you determine preferred formulary alternatives are not clinically appropriate for specific patients, you will need to obtain prior authorization (PA) to continue coverage beyond the applicable effective date.

What if I need assistance?

We recognize the unique aspects of patient cases. If your Amerigroup patient cannot be converted to a formulary alternative for medical reasons, call our Pharmacy department at **1-800-454-3730** and follow the voice prompts for pharmacy PA. You can find the *Preferred Drug List* on our provider website at <https://providers.amerigroup.com/NJ>.

If you need assistance with any other item, contact your local Provider Relations representative or call Provider Services at **1-800-454-3730**.